Defining a drug's value

Illustration: Sarah Grillo/Axios

Over the past few years, there’s been a growing push from researchers to figure out which drugs are worth their price tags.

Other countries, like the U.K., attempt to answer that question with governmental bodies of experts who determine how much value certain drugs provide, compared to their price. The U.S. doesn’t have such an organization, in part because the pharmaceutical industry hates the idea.

Where it stands: The independent Institute for Clinical and Economic Review, or ICER, has tried to fill that void here.

  • ICER said the expensive new cancer therapies known as CAR-T, which can cost as much as $500,000, are for the most part reasonably priced.
  • There’s a similar debate over new hepatitis C drugs, which have list prices near $100,000 per treatment and are essentially a cure, preventing expensive hospitalizations down the line.
  • ICER already works with the Department of Veterans Affairs to help determine which drugs it should and shouldn’t cover.

Yes, but: “The fact that we can spread a price across thousands or millions of people does not justify a given price,” Walid Gellad, a medical and pharmaceutical professor at the University of Pittsburgh, recently mused.

Go deeper: Read the rest of Axios' Deep Dive on prescription drug prices

What's next

New York Times endorses Elizabeth Warren and Amy Klobuchar for president

Democratic presidential candidates Sens. Elizabeth Warrenand Sen. Amy Klobuchar at the December 2020 debatein Los Angeles. Photo: Justin Sullivan/Getty Images

The New York Times editorial board has endorsed Sens. Elizabeth Warren and Amy Klobuchar for president, in a decision announced on national television Sunday night.

Why it matters: The board writes in its editorial that its decision to endorse two candidates is a major break with convention that's intended to address the "realist" and "radical" models being presented to voters by the 2020 Democratic field.

Go deeperArrow1 hour ago - Media

What's next in the impeachment witness battle

Sens. Susan Collins (R-Maine) and Lisa Murkowski (R-Alaska). Photo: Tom Williams/CQ-Roll Call, Inc via Getty Images

Senators will almost certainly get to vote on whether or not to call impeachment witnesses. The resolution laying out the rules of the trial, which will be presented Tuesday, is expected to mandate that senators can take up-or-down votes on calling for witnesses and documents.

Yes, but: Those votes won't come until the House impeachment managers and President Trump's defense team deliver their opening arguments and field Senators' questions.

Inside Trump's impeachment strategy: The national security card

White House counsel Pat Cipollone and acting Chief of Staff Mick Mulvaney. Photo: Jabin Botsford/The Washington Post via Getty Images

Trump officials say they feel especially bullish about one key argument against calling additional impeachment witnesses: It could compromise America's national security.

The big picture: People close to the president say their most compelling argument to persuade nervous Republican senators to vote against calling new witnesses is the claim that they're protecting national security.